Penn Engineering Launches Collaboration with the Center for Targeted Therapeutics and Translational Nanomedicine (CT3N)

Penn Engineering has joined with the Perelman School of Medicine (PSOM) in The Center for Targeted Therapeutics and Translational Nanomedicine (CT3N), an interdisciplinary venture with the mission of facilitating and accelerating translational research in targeted therapeutics and nanomedicines. This collaboration brings together leading laboratories active in these areas at the University of Pennsylvania, Children's Hospital of Philadelphia (CHOP) and surrounding academic institutions. The center was originally established in 2010 with the suppot of the Insitute for Translational Medicine and Therapeutics (ITMAT) and the Clinical and Translational Research Award (CTSA).
"The transformation of CT3N into a joint Penn Engineering/PSOM center will draw more engineering faculty and students into the field," said Kathleen Stebe, Chair of the CT3N Advisory Board and Richer & Elizabeth Goodwin Professor in Chemical and Biomolecular Engineering. "In synergy with researchers from PSOM, this new cohort will drive science and engineering breakthroughs to create the next generation of personalized therapeutics."

Currently, CT3N includes 19 faculty members from Penn Engineering, in addition to Stebe, who is also Deputy Dean for Research and Innovation at Penn Engineering, and Andrew Tsourkas, Co-Director of CT3N and Professor in Bioengineering. "By joining CT3N, Engineering will transform the Center into an even more interdisciplinary endeavor, allowing discoveries in the fundamental sciences to be exploited for biomedical applications at a much earlier stage," said Tsourkas.

Research areas being pursued by CT3N faculty include design of biomaterials and carriers for drug delivery; identification of molecular targets for cell-specific delivery; studies of targeting, binding, sub-cellular trafficking; and metabolism of targeted drugs. These studies use modern strategies of nanotechnology, bioconjugation and recombinant fusion proteins, phage display libraries, cellular grafting, monoclonal antibodies, bioengineering, computational modeling, and diverse imaging modalities. The efficacy and safety of novel therapeutic approaches are evaluated in a wide range of cell culture and animal models.

To seed new collaborations, CT3N will solicit proposals from interdisciplinary research teams.  This support is made possible by the generous support of the Brassington family, and funds from the Vice Provost for Research, Penn Engineering and the Perelman School of Medicine. 

Return to News Features